How it works
All cells release DNA into the bloodstream. Using a single blood test, the Galleri® test examines the DNA in your bloodstream to determine if any could have originated from cancer cells (i.e. a cancer signal is detected). If so, the test is able to predict with 90% accuracy where in the body the cancer cells may have originated from.
The Galleri® test has the capability to screen many types of cancers earlier, such as those that do not have screening tests, or those that are generally rarer or more lethal, like ovarian and pancreatic cancers. Generally, these cancers are not discovered until symptoms appear, which happens later in the disease process. Early detection allows for earlier treatment intervention, optimizing patient outcomes.
Galleri® test results are generally available 2 weeks after the scheduled blood draw.
Results should be interpreted by a healthcare provider in the context of a patient’s medical history and clinical findings. Results are separated into two categories: “No Cancer Signal Detected” and “Cancer Signal Detected”. A result of “No Cancer Signal Detected” does not rule out cancer. A result of “Cancer Signal Detected” requires diagnostic evaluation to confirm a cancer diagnosis.*
*False-positive results (a cancer signal is detected when cancer is not present) and false-negative results (a cancer signal is not detected when cancer is present) do occur.
HerMD has partnered with the team at Galleri® to offer the Galleri® test to our patients. The test is recommended for use annually in adults with a high risk of cancer, such as those who are aged 50+ years. At HerMD, we also offer the Galleri® test to patients who are negative for genetic mutations, but have a strong family history of cancer.
The cost associated with the Galleri® test is $949, which is paid out-of-pocket. However, FSA and HSAs can also be used to cover the cost associated with the Galleri® test.
The Galleri® test is not FDA-approved. It is not a genetic test, and it does not detect all types of cancers. Use of the Galleri® test is not recommended in individuals who are pregnant, 21 or younger, or undergoing active cancer treatment. The Galleri® test is not a substitute for routine and individual cancer screenings, and it is important to continue with these screenings to help maximize early detection.